Authors

Latest:

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

William B. Donnellan, MD

Latest:

Dr. Donnellan Discusses Trials in Hematologic Malignancies

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

William C. Huang, MD

Latest:

Dr. Huang on the Widespread Adoption of Robotic Surgery for Bladder Surgery

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.

William Carroll, MD

Latest:

Making Progress in Treating Relapse in Childhood Leukemia

Having a robust armamentarium to treat childhood acute lymphoblastic leukemia (ALL) is a major triumph in oncology.

William D. Tap, MD

Latest:

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

William D. Tap, MD, Memorial Sloan Kettering Cancer Center

William Eward, MD, DVM

Latest:

Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

William F. Symmans, MB, ChB

Latest:

Dr. Symmans on Moon Shots Program for Patients With TNBC

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

William F. Symmans, MD

Latest:

Dr. Symmans on the Staging System for Breast Cancer

William F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.

William G. Blum, MD

Latest:

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

William G. Wierda, MD

Latest:

Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLL

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

William G. Wierda, MD, PhD

Latest:

Dr Wierda on the Genomic Evolution of Pirtobrutinib in Pretreated CLL

William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center

William G. Wierda, MD, PhD, University of Texas MD Anderson Cancer Center

William G Wierda, MD, University of Texas MD Anderson Cancer Center

Latest:

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

William Gradishar, MD,

Latest:

Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment Algorithm

William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.

William I. Bensinger, MD, Swedish Cancer Institute

William J. Gradishar, MD

Latest:

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

William J. Gradishar, MD, FASCO

Latest:

New Strategies Shift Landscape in HR+ Metastatic Breast Cancer

There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.

William J. Gradishar, MD, Northwestern